DexCom (DXCM) Director Nicholas Augustinos Receives RSU Award

What Happened

• Nicholas Augustinos, a director of DexCom, was granted 5,575 restricted stock units (RSUs) on May 28, 2026. The Form 4 lists the acquisition price as $0.00 because this transaction is an award (grant) of RSUs rather than an open‑market purchase. The filing (accession 0001093557-26-000123) was submitted on June 1, 2026.
• The filing does not state a cash value or the amount of DexCom shares owned by Augustinos after the grant. RSUs convert to common stock only upon settlement/vesting.

Key Details

• Transaction date: 2026-05-28 (grant); Form 4 filed: 2026-06-01 (timely).
• Transaction type/code: A — Award/Grant of RSUs; Price reported: $0.00 (typical for equity awards).
• Vesting: 100% of the RSU award vests on the earlier of the one‑year anniversary of the grant (May 28, 2027) or DexCom’s 2027 Annual Meeting of Stockholders. Each RSU represents a contingent right to one share upon settlement. (Footnote F1)
• Ownership/holding: Shares are held by the Kirschner/Augustinos Revocable Trust, for which the reporting person is a trustee. (Footnote F2)
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: filed within a few days of the grant; no late‑filing indication.

Context

• RSU grants are a form of compensation and represent a contingent right to receive shares at vesting; they are not immediate purchases or sales and do not necessarily signal a trading view. For retail investors, purchases by insiders can be more directly informative; grants are common for directors and executives as part of pay/retention.